Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan J Korman

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Cancer Immunology Research|April 5, 2017
Masterful Antibodies: Checkpoint BlockadeNils Lonberg, Alan J Korman
Trends in Molecular Medicine|November 1, 2024
Fc-optimized checkpoint antibodies for cancer immunotherapyRony Dahan, Alan J Korman
Journal for Immunotherapy of Cancer|November 17, 2025
Endothelial cells as targets of immune checkpoint blockadeAlan J Korman, Matthew Taylor, F Stephen Hodi
Advances in Immunology|May 30, 2006
Checkpoint blockade in cancer immunotherapyAlan J Korman, Karl S Peggs, James P Allison
Nature Reviews. Drug Discovery|December 23, 2021
The foundations of immune checkpoint blockade and the ipilimumab approval decennialAlan J Korman, Sarah C Garrett-Thomson, Nils Lonberg
Current Opinion in Immunology|February 9, 2006
Principles and use of anti-CTLA4 antibody in human cancer immunotherapyKarl S Peggs, Sergio A Quezada, Alan J Korman, et al.
Oncoimmunology|November 22, 2012
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any moreMeghan E Turnis, Alan J Korman, Charles G Drake, et al.
Cancer Cell|September 17, 2015
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisRony Dahan, Emanuela Sega, John Engelhardt, et al.
The Journal of Experimental Medicine|July 8, 2009
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodiesKarl S Peggs, Sergio A Quezada, Cynthia A Chambers, et al.
Journal of Translational Medicine|May 30, 2012
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011Ivan Martinez Forero, Hideho Okada, Suzanne L Topalian, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Cancer Immunology Research|April 5, 2017
Masterful Antibodies: Checkpoint BlockadeNils Lonberg, Alan J Korman
Trends in Molecular Medicine|November 1, 2024
Fc-optimized checkpoint antibodies for cancer immunotherapyRony Dahan, Alan J Korman
Journal for Immunotherapy of Cancer|November 17, 2025
Endothelial cells as targets of immune checkpoint blockadeAlan J Korman, Matthew Taylor, F Stephen Hodi
Advances in Immunology|May 30, 2006
Checkpoint blockade in cancer immunotherapyAlan J Korman, Karl S Peggs, James P Allison
Nature Reviews. Drug Discovery|December 23, 2021
The foundations of immune checkpoint blockade and the ipilimumab approval decennialAlan J Korman, Sarah C Garrett-Thomson, Nils Lonberg
Current Opinion in Immunology|February 9, 2006
Principles and use of anti-CTLA4 antibody in human cancer immunotherapyKarl S Peggs, Sergio A Quezada, Alan J Korman, et al.
Oncoimmunology|November 22, 2012
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any moreMeghan E Turnis, Alan J Korman, Charles G Drake, et al.
Cancer Cell|September 17, 2015
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisRony Dahan, Emanuela Sega, John Engelhardt, et al.
The Journal of Experimental Medicine|July 8, 2009
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodiesKarl S Peggs, Sergio A Quezada, Cynthia A Chambers, et al.
Journal of Translational Medicine|May 30, 2012
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011Ivan Martinez Forero, Hideho Okada, Suzanne L Topalian, et al.
Pageof 7